RCMNY
KURA icon

Rubric Capital Management (New York)’s Kura Oncology KURA Stock Holding History

Rubric Capital Management (New York)’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400,000
Closed -$7.49M – 77
2021
Q3 		$7.49M Buy
400,000
+168,519
+73% +$3.18M 0.21% 45
2021
Q2 		$4.83M Buy
+231,481
New +$5.75M 0.3% 48

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Rubric Capital Management (New York)'s KURA Position: Q4 2021 in Review

Rubric Capital Management (New York) sold out of Kura Oncology (KURA) in Q4 2021, closing a stake of 400,000 shares — an estimated $7.49M sold.

Rubric Capital Management (New York) first reported a position in KURA in Q2 2021 and held it in 2 quarters. The position peaked at $7.49M in Q3 2021. 151 funds tracked by Wall St. Rank hold KURA as of Q4 2021.

  • Rubric Capital Management (New York) reported no remaining Kura Oncology position as of Q4 2021 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 400,000 Kura Oncology shares in Q4 2021, an estimated $7.49M.
  • Rubric Capital Management (New York) first reported a position in Kura Oncology in Q2 2021 and held it in 2 quarters.
  • Rubric Capital Management (New York)'s Kura Oncology position peaked at $7.49M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2021.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.